Solid Tumors Clinical Trial
Official title:
Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors
Verified date | October 2019 |
Source | Shanghai Junshi Bioscience Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with advanced solid tumors.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 2018 |
Est. primary completion date | September 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Histological or cytological diagnosis of advanced or recurrent adenocarcinoma of solid tumor, including adenocarcinoma of the stomach or gastro-esophageal junction, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, cholangiocarcinoma, Pancreatic ductal cell carcinoma, etc. - at least one prior chemotherapy regimen - age between 18 and 75 years, both gender - has at least one measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST V1.1) 2. life expectancy = 3 months 3. ECOG performance status of 0 or 1 4. Has had last dose of chemotherapy more than 4 weeks prior to the first dose of study therapy JS001, and has recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Grade 1 or better from the AEs due to the chemotherapy. 5. Has had last administration of radioactive therapy more than 4 weeks prior to the first dose of study therapy JS001. 6. Has had last administration of immunosuppressive systemic steroid therapy (more than 10 mg/d prednisone or equal dose) more than 2 weeks prior to the first dose of study therapy JS001. 7. Has undergone major surgery that needs general anesthesia more than 4 weeks prior to the first dose of study therapy JS001. Has undergone surgery that needs local anesthesia or epidural anesthesia more than 72 hours prior to the first dose of study therapy JS001 and has already recovered from the surgery. Has undergone biopsy more than 1 hour prior to the first dose of study therapy JS001. 8. The lab examination results of the screening must fulfill all of the following: - absolute neutrophil count more than or equal to 1.5×109/ L - platelet count more than or equal to 90×109/ L - hemoglobin more than or equal to 90 g/L - creatinine less than or equal to132.6µmol/L or creatinine clearance >40 mL/min - aspartate transferase(AST) and alanine transferase(ALT) less than or equal to 3.0 ×ULN - total bilirubin less than or equal to 1.5×ULN( except for the patients with Gilbert syndrome, whose total bilirubin ,must less than or equal to 51.3µmol/L) 9. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study related activities. 10. Able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: 1. Has had antineoplastic herbal therapy within 2 weeks prior to the first dose of study therapy JS001. 2. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and receive study therapy or used an investigational device within 4 weeks of the first dose of study drug. 3. Has a medical condition that requires chronic systemic steroid therapy or on any other form of immunosuppressive medication. 4. Has a known history of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the participant has undergone potentially curative therapy with no evidence of that disease for 5 years. 5. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 6. Has interstitial lung disease OR has had a history of pneumonitis that has required oral or IV steroids. 7. Has active or suspected autoimmune disease except leukoderma,type I Diabetes, Residual hypothyroidism that induced by autoimmune thyroiditis and only requires the use of hormone replacement therapy, Or disease that rarely relapse without external stimulating factors. 8. Had prior treatment targeting PD-1: anti-PD-1,anti-PD-L1, anti-PD-L2, cytotoxic T-lymphocyte-associated protein (CTLA), or other antibodies that targeting T cell costimulatory pathway or checkpoint. 9. Has an active infection requiring systematic therapy. 10. Is positive for Human Immunodeficiency Virus (HIV). 11. Has active Tuberculosis. 12. Has known active Hepatitis B or C. 13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. 14. Has received or will receive a live vaccine within 30 days prior to the first administration of study drug. 15. Is pregnant or breastfeeding. 16. Cannot tolerate vein puncture and / or venous access. 17. Any other conclusive medical reasons, mental illness, and / or social reasons that determined by the investigators. |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen UniversityCancer center | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Shanghai Junshi Bioscience Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment | Up to 2 approximately years | ||
Secondary | Anti-Drug Antibody of JS001 in Chinese patients | Cycle 1,2,3,5 Day 1 before JS001 infusion and 336 hours after last JS001 infusion, each cycle is 28 days. | ||
Secondary | Objective Response Rate (ORR) | Up to 2 approximately years | ||
Secondary | Duration of Response (DOR) | Up to 2 approximately years | ||
Secondary | Progression-Free survival (PFS) | Up to 2 approximately years | ||
Secondary | Overall Survival (OS) | Up to 2 approximately years | ||
Secondary | DLT in patients with solid tumor treated with JS001. | Cycle 1(each cycle is 28 days) | ||
Secondary | PD-1 receptor occupancy of blood | 1 year | ||
Secondary | Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb) | 1 year | ||
Secondary | Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb | 1 year | ||
Secondary | Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb Area Under the Curve [AUC]). Area Under the Curve (AUC) after single dose injection of Recombinant Humanized Anti-PD-1 Monoclonal Antibody | 1 year | ||
Secondary | t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb | 1 year | ||
Secondary | Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb | 1 year | ||
Secondary | Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb | 1 year | ||
Secondary | Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb | 1 year | ||
Secondary | Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb | 1 year | ||
Secondary | Degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb | 1 year | ||
Secondary | Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |